Two new studies have identified why Actemra may not be an effective CRS treatment and, importantly, why a different medication may be much more effective.
Genomics will change what patients expect from their provider, as well as change how physicians treat them. Before this happens, education on both sides is needed. This month we look at some of the big talking points.
The study of viral ecology is taking major leaps forward with the use of long-read sequencing and viral metagenomics. On this webinar we discuss how MinION technology is bringing scientists closer to high-throughput single-virus genomics from environmental samples.
The genomes of more than 3000 of these bacteria have been mapped by scientists in order to better understand diseases and the mechanisms of antibiotic resistance.
A new study provides a unique look at a novel strategy — clinical trials in a dish — that bridges preclinical testing and clinical trials.
Some regulatory hurdles for makers of direct-to-consumer genetic health risk test have been lifted by the US Food and Drug Administration.
A security breach at DNA testing website MyHeritage have leaked the data of over 92 million users, the company said on Monday.
Yesterday’s news about the Oncotype DX test that could enable a lot of patients with breast cancer to safely forgo chemotherapy, is massive news for the breast cancer field. But it’s also big news for Genomic Health, the developer of the test.
A patient with metastatic breast cancer has made a dramatic recovery after receiving a personalised therapy using her own cells.
New findings suggest that a person’s own immune system helps nudge him or her down the path toward Parkinson’s, and that restraining the immune system with drugs potentially could prevent the neurological disorder.
People’s medical and health history might become more than just a blueprint for doctor’s actions, now that blockchain start-up Nebula Genomics, and Hong Kong-based Longenesis are partnering up.
ASCO checkpoint inhibitor battle between Merck and Roche highlights the pitfalls in directly comparing clinical trial results in the era of precision medicine.